MEDBOT-B (02252) is expected to incur a net loss of no more than 240 million yuan in 2025 after adjustment.

MEDBOT-B (02252) announces that the Board of Directors expects the company's revenue for the year ending December 31, 2025 to increase by approximately 110% to 120% compared to the year ending December 31, 2024. This significant increase is mainly attributed to the breakthrough commercialization of the core product "Tumai Endoscopic Surgery" by Siasun Robot & Automation, with rapid sales growth. Particularly, the expansion of Tumai in overseas markets has been remarkable, with over a hundred new orders from overseas markets throughout the year, resulting in overseas market sales revenue more than five times that of last year. The growth rate far exceeds the industry average, demonstrating strong global expansion momentum. As of the date of this announcement, Tumai has accumulated over 180 commercial orders globally, with the cumulative installation volume exceeding 120 units. The Board of Directors expects the Group to achieve a net loss not exceeding RMB 240 million for the fiscal year ending December 31, 2025, narrowing by over 50% compared to the adjusted net loss for the year ending December 31, 2024 (approximately RMB 482 million). This narrowing of the loss is mainly attributed to rapid growth in operating income, as well as significant reductions in product costs and operating expenses through various cost reduction and efficiency improvement measures. Additionally, thanks to the Group's efficient cash flow management measures, the Group's net outflow of free cash flow for the year ending December 31, 2025 is expected to narrow by over 80% compared to the year ending December 31, 2024, to not exceed RMB 70 million.